InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development
InterVenn Biosciences today announced the completion of a $201 million Series C financing.
- InterVenn Biosciences today announced the completion of a $201 million Series C financing.
- To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications.
- InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
- For more information about InterVenn Biosciences, please visit the companys website .